Show overview
The Biopharma Pod has been publishing since 2009, and across the 14 years since has built a catalogue of 18 episodes. That works out to roughly 2 hours of audio in total. Releases follow an irregular cadence.
Episodes typically run under ten minutes — most land between 4 min and 6 min — though episode length varies meaningfully from one episode to the next. None of the episodes are flagged explicit by the publisher. It is catalogued as a EN-language News show.
The catalogue appears to be on hiatus or wound down — the most recent episode landed 2.6 years ago, with no new episodes in over a year. Published by William Reed Ltd.
From the publisher
Brought to you by the team behind BioPharma-Reporter.com
Latest Episodes
Podcast: The British start-up taking psychedelic therapy mainstream
In our first podcast interview of 2023, BioPharma Reporter spoke with Dr Sarah Bateup, therapy lead at Clerkenwell Health, about the potential of psychedelic medicine and her work within the psychedelic therapy training space.
What kind of consistency can industry expect from the FDA post pandemic?
How the US Food and Drug Administration (FDA) exercises flexibility has been an important and emerging issue for the past several years.
Chicago emerging as a life science and biopharma hub
Many turn to Boston and North Carolina’s Research Triangle to set up life science companies, but Chicago is now also fast becoming a draw in this respect. The city is emerging as a life science and biopharma hub and seems poised for even further growth, in CGT in particular.
Will Biden backed bills boost biosimilars uptake in the US?
Today we are launching a new series called The BioPharma Pod. Kicking off these broadcasts is the hot topic of biosimilars.
Bioproduction bottlenecks increasing due to staff shortages, says report
A shortage in expertise is causing bottlenecks in the biomanufacturing space with around half of drugmakers struggling to fill processing positions, an industry report finds.
'The sexiness of the ADC world' - CMOs talk antibody-drug hybrids at CPhI
Piramal’s COO Vijay Shah described antibody-drug conjugates (ADCs) as “a concept whose time has come” at the CPhI annual report press conference and recent investors in the technology echo his words.
Better single-use cross flow techs still needed says GE Healthcare
The biopharmaceutical manufacturing sector needs better cross flow filtration technologies according to GE Healthcare, which says that advances in bioreactor systems have not been matched downstream.
Immunocore CEO: 3rd Big Pharma Eying Unique Cancer Targeting Tech
Immunocore is looking for more licensees for its cancer targeting technology following recent discovery and development deals with GSK and Genentech.
Customers to Save up to 65% as ASI and Chromatan Pen Single-Use Deal
ASI has teamed up with Chromatan in order to deliver single-use and column-free capture purification services which could save clients 65% in chromatography costs in clinical manufacturing.
ATMI: Single Use Bioreactors on the Up, but US Tails Europe
New innovations in single-use bioprocessing systems are being picked up quicker in Europe than in the US, according to ATMI.
The single-use age has dawned, says ThermoFisher
Developments in single-use technology signals the end for clean-in-place biomanufacturing methods, according to ThermoFisher’s Bill Whitford.
European CMO market will double in just 6 years, says Frost & Sullivan
The European CMO sector is set to double in the next six years and will hit revenues of up to $20.75bn, according to Frost & Sullivan’s Aiswariya Chidambaram.
Acuros in talks with Big Pharma over water-powered delivery pump
Acuros is seeking development partnerships with Big Pharma over its recently launched water-powered drug delivery pump.
Unilife launches Autoinfuser range publically
Unilife is expanding its large dose delivery platform in a bid to meet a “growing industry need” for at-home drug administration in bigger scale.
EMD Millipore talks integration: of processes; and with owner Merck KGaA
The biomanufacturing industry needs to adopt an integrated approach to upstream and downstream processing to boost efficiency and productivity according to EMD Millipore.
OctoPlus, Glycotope, Merck KGaA and SCM Pharma on BioPh 2009
How successful was the BioPh conference in Madrid? in-PharmaTechnologist asked key players attending the inaugural event.
Gene therapy to drive viral and biologics market, says SAFC
SAFC Pharma has added extra viral and biologics capacity at its California plant in a $12m project that allows it to take projects from the lab to commercial scale.
BIO 2009: snapshot of an evolving biotech industry
in-Pharmatechnologist's Nick Taylor looks back on BIO 2009, an event at which uncertainty about the development of the biotechnology industry’s future shape dominated proceedings.